Drugs Manufactured With A Forged License, FIR Lodged, Drugs Worth 23.93 Lakhs Seized

Hyderabad: Drugs Control Administration, Telangana, has detected a significant case of fraudulent activity within the pharmaceutical industry. An investigation conducted by DCA officials has revealed that Ovoid Pharmachem Pvt. Ltd., located at Plot No. 318, Subashnagar, Quthbullapur Mandal, Medchal-Malkajgiri District, engaged in the forgery of a drug manufacturing license.

VB Kamalasan Reddy (IPS), Director General, DCA Telangana said in a press release that “Narasapally Ramudu, Director of Ovoid Pharmachem Pvt. Ltd., was involved in the creation of a forged Drug Manufacturing license in Form-25, bearing No. TS/MFG2019-43319, L.Dis.No: 315995/TS/2022 dated: 05/07/2022, for certain drug products which were not authorized for the company by the Drugs Control Administration, Telangana. This unlawful activity was carried out with the intention to deceive drug regulatory authorities, pharmaceutical manufacturers, distributors, and the public.

Upon verification of the Drugs Control Administration, Telangana licensing database on the ODLS (Online Drug Licensing System) Portal, it has been confirmed that Ovoid Pharmachem Pvt. Ltd. created a fake drug licence for certain drug products.

DCA also detected that the firm manufactured and sold certain drug products under this fraudulent license. Drugs Control Administration officials seized stocks worth Rs. 23.93 lakhs, including 800 Kgs of Activated Charcoal 250 mg and Simethicone 80 mg Pellets.”

Drugs Control Administration, Telangana, has filed a complaint with the Jeedimetla Police Station. FIR No. 327/2024 has been registered on 05-04-2024 against Mr. Narasapally Ramudu, Director of Ovoid Pharmachem Pvt. Ltd., under Sections 420 (Cheating) and 468 (Forgery) of the Indian Penal Code (IPC).

It is imperative to emphasize that the manufacturing and sale of pharmaceutical products under forged licenses pose a significant threat to public health and safety. All manufacturers shall comply strictly with regulatory requirements and maintain the highest standards of ethical conduct.

Related Posts

  • Pharma
  • May 31, 2025
  • 116 views
Generic drugs can bring hope for SMA patients’

Dr Ann Agnes Mathew, a consultant paediatric neurologist and neuromuscular specialist based in Bengaluru, treats nearly 600 SMA patients from across India. In an interview with DH’s Udbhavi Balakrishna, she…

  • Pharma
  • May 31, 2025
  • 105 views
47% of pharma MOUs from VGGS 2024 commissioned

Gandhinagar:  The state govt said that 47% of MoUs signed in the pharmaceutical sector in the Vibrant Gujarat Global Summit (VGGS) 2024 have been commissioned. It said on Friday that…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Generic drugs can bring hope for SMA patients’

Generic drugs can bring hope for SMA patients’

47% of pharma MOUs from VGGS 2024 commissioned

47% of pharma MOUs from VGGS 2024 commissioned

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

AstraZeneca gets CDSCO nod for lung cancer drug

AstraZeneca gets CDSCO nod for lung cancer drug